MMSI · Merit Medical Systems Inc
$91.98
+2.72 (+3.05%)
At close · Aug 19
Market Cap
$5.36B
Shares
59.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$91.98
Open$89.98
Day$89.98–91.99
52W close$60.31–93.18
Avg vol 30d1.0M
Short int3.7M · 6.3% float · 3.7d
Short vol70%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+20%
above
RSI (14)
78
overbought
MACD trend
Negative
52-week position
96%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+26%
trailing
6-month return
+18%
trailing
YTD return
+4%
this year
Relative strength
+6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $76 › 200d $76 — 200d above 50d
Institutional flow
Distributing
-0% holders QoQ · +65 funds added
Insider flow
Distributing
Net -$1.8M over 90 days · 100% sells
Short interest
Rising
6.26% of float · ▲ +8.7% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
401 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
Gross margin
49%
expanding
EPS growth
+5%
Y/Y
Free cash flow
$215.7M
Valuation
P/E 36.9
in line
Balance sheet
$298.9M
net debt
Quant / Vol
risk profile
Volatility
31%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Total Revenue
· Year Ending December 31, 2026
Initiated
$1.63B – $1.64B
prior FY $1.52B
midpoint +8.0% Y/Y
Non-GAAP Earnings Per Share
· Year Ending December 31, 2026
Non-GAAP
Initiated
$4.25 – $4.35
Prior guidance
period ended
· from the 8-K filed Oct 30, 2025
Net Sales
· Year Ending December 31, 2025
$1.5B – $1.52B
Cardiovascular Segment
· Year Ending December 31, 2025
$1.43B – $1.44B
Endoscopy Segment
· Year Ending December 31, 2025
$72M – $74M
Guided vs delivered
· last 1 settled
Net Sales
Year Ending December 31, 2025
guided $1.5B – $1.52B
$1.52B
Beat +0.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
78
Bearish
MACD trend
Negative
Bearish
52-week position
96%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $76 › 200d $76 — 200d above 50d
Institutional flow
Distributing
-0% holders QoQ · +65 funds added
Insider flow
Distributing
Net -$1.8M over 90 days · 100% sells
Short interest
Rising
6.26% of float · ▲ +8.7% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
401 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $60
Now $92 · 96%
Range high $93
vs 200-day avg +20%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Constant Currency Revenue non-GAAP | 789.8M | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Reported Revenue 800.72M
-10.92M Impact of foreign exchange
= Constant Currency Revenue 789.8M
|
|||
| Constant Currency Revenue, Organic non-GAAP | 774.45M | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Constant Currency Revenue 789.8M
-13.7M Revenue from certain acquisitions
-1.64M Revenue from divestitures (b)
= Constant Currency Revenue, Organic 774.45M
|
|||
| Free Cash Flow non-GAAP | 76.62M | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Reported Cash Flow from Operations 109.96M
-33.34M Capital Expenditures
= Free Cash Flow 76.62M
|
|||
| Non-GAAP EPS non-GAAP | $2.13 | Six Months Ended June 30, 2026 | — |
| Non-GAAP Gross Margin non-GAAP | 54.6% | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Reported Gross Margin $50
+$4.6 Amortization of intangibles
+$0 Inventory mark-up related to acquisitions
= Non-GAAP Gross Margin $54.6
|
|||
| Non-GAAP Net Income non-GAAP | 127.94M | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net income 79.8M
+28.22M Amortization of intangibles (Cost of Sales)
-29K Contingent consideration benefit
+3.78M Amortization of intangibles (Operating Expenses)
+11.37M Performance-based share-based compensation (a)
+1.65M Corporate restructuring (b)
+5.91M Acquisition-related
+1.58M Medical Device Regulation expenses (c)
+6.03M Long-term debt costs (e)
-10.98M Gain on disposal of business unit
+618K Other non-operating loss (f)
= Non-GAAP net income 127.94M
|
|||
| Non-GAAP Operating Income non-GAAP | 169.89M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Operating Margin non-GAAP | 21.2% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MMSI
this stock
Merit Medical Systems Inc
|
$5.36B | +4.4% | +11.8% | 36.9 | 6.3% |
|
ISRG
Intuitive Surgical Inc
|
$140.51B | -29.8% | +20.5% | 45.7 | 1.9% |
|
BDX
Becton Dickinson & Co
|
$49.24B | — | +8.2% | — | 3.7% |
|
MDLN
Medline Inc.
|
$45.86B | -19.3% | +11.5% | — | 2.6% |
|
ALC
Alcon Inc
|
$35.55B | -5.8% | +10.5% | — | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MMSI | +0.9% | +25.8% | +17.9% | +8.2% | +4.4% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +1.3% | +22.9% | +6.3% | +5.3% | -8.4% |
Capital returns
Buyback program
· as of Apr 30, 2007
Authorized
shares 1.40M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.